A retrospective analysis of optimal timing of thoracic radiotherapy for driver gene ‐negative metastatic non‐small cell lung cancer
ConclusionThe addition of TRT during the pre-emptive no progression phase was associated with a significantly longer PFS than during the delayed slow progression phase and had an acceptable safety profile. Our results might support the earlier initiation of TRT after induction therapy for some patients with driver-gene-negative mNSCLC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - February 7, 2024 Category: Cancer & Oncology Authors: Yanan Wang,
Zhenhua Gao,
Wen Zhao,
Hongxin Li,
Xue Meng,
Jisheng Li Tags: ORIGINAL ARTICLE Source Type: research
Genomic evolutional analysis of surgical resected specimen to assess osimertinib as a first ‐line therapy in two patients with lung cancer harboring EGFR mutation: Case series
Gene aberrations alter in form dramatically; clonal evolution Clinical presentation of intrinsic resistant mechanism. AbstractEpidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is crucial for patients with lung cancer harboringEGFR mutations. However, almost all patients experience disease progression, regardless of their response to the targeted therapy, necessitating the development of additional treatment options. Two patients with lung cancer harboringEGFR-L858R mutations in exon 21 were treated by surgical resection during successful osimertinib treatment. Because the pathological diagnosis was su...
Source: Thoracic Cancer - February 7, 2024 Category: Cancer & Oncology Authors: Hayato Koba,
Taro Yoneda,
Hiroko Morita,
Hideharu Kimura,
Yuya Murase,
Nanao Terada,
Yuichi Tambo,
Masafumi Horie,
Kazuo Kasahara,
Isao Matsumoto,
Seiji Yano Tags: BRIEF REPORT Source Type: research
Single ‐cell sequencing reveals the immune landscape of breast cancer patients with brain metastasis
ConclusionsThe scRNA-seq in CSF provides a noninvasive method to describe the TME of breast cancer patients and guide immunotherapy. (Source: Thoracic Cancer)
Source: Thoracic Cancer - February 6, 2024 Category: Cancer & Oncology Authors: Huaping Zhou,
Xiang He,
Jia Huang,
Yumin Zhong,
Leyao Zhang,
Xiang Ao,
Hailin Zhao,
Su Hu,
Hongsheng Li,
Jianqing Huang,
Hongxin Huang,
Hongling Liang Tags: ORIGINAL ARTICLE Source Type: research
Trends in pain undertreatment among lung cancer patients at the EOL: Analysis of urban city medical insurance data in China
ConclusionTerminal lung cancer populations in urban China have experienced reduced access to opioids at the EOL. The clinicians did not prescribe a satisfactory dose of opioids per prescription, while the patients suffered increasing pain in the last 30 days of life. Sufficient opioid analgesic administration should be advocated for lung cancer patients during the EOL period. (Source: Thoracic Cancer)
Source: Thoracic Cancer - February 6, 2024 Category: Cancer & Oncology Authors: Jiani Zheng,
Yihua Huang,
Junyi He,
Huangqiang Zhou,
Tingting Liu,
Jie Huang,
Mengting Shi,
Yuanyuan Zhao,
Wenfeng Fang,
Yunpeng Yang,
Li Zhang Tags: ORIGINAL ARTICLE Source Type: research
Surgical resection of an intraluminal tumor in the azygos vein with an unknown primary site causing superior vena cava syndrome
We report a case of SVC syndrome caused by an intraluminal tumor in the azygos vein. Surgical resection should be considered as a treatment of choice for the management of SVC syndrome caused by an intraluminal malignancy in the azygos vein. AbstractIntraluminal tumor in the azygos vein is a rare disease that can cause superior vena cava (SVC) syndrome. Radiotherapy and endovascular stenting with or without chemotherapy are reported to have a high clinical success rate for the management of SVC syndrome with malignancy, but a poor survival rate. Here, we report a 69-year-old man who presented with swelling of the face and ...
Source: Thoracic Cancer - February 6, 2024 Category: Cancer & Oncology Authors: Yuki Monden,
Dai Une,
Hidejiro Torigoe,
Tetsuya Isoda,
Suzuka Kamaguchi,
Kenji Yoshida,
Yuji Hirami,
Mikizo Nakai Tags: CASE REPORT Source Type: research
Global burden of esophageal cancer attributable to high BMI in 204 countries and territories: 1990 –2019
ConclusionsThe incidence of EC is increasing, particularly in developing nations, which may be attributed to the prevalence of high BMI. To mitigate the impact of high BMI on the incidence of EC, it is important to increase awareness of its deleterious effects, which may alleviate the burden of this disease. (Source: Thoracic Cancer)
Source: Thoracic Cancer - February 6, 2024 Category: Cancer & Oncology Authors: Zhiming Chen,
Xingxing Zhang,
Jianxue Zhai,
Jiayang Fan,
Yikuan Cai,
Tianlan Ye,
Zhizhi Wang,
Kaican Cai Tags: ORIGINAL ARTICLE Source Type: research
Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma
ConclusionCamrelizumab plus albumin paclitaxel and carboplatin were found to be safe and effective in the neoadjuvant treatment of borderline resectable or unresectable locally advanced esophageal cancer. It was observed to improve the rate of curative resection without increasing perioperative complications. (Source: Thoracic Cancer)
Source: Thoracic Cancer - February 6, 2024 Category: Cancer & Oncology Authors: Li Chao,
Jianting Liu,
Yun Chen,
Yuhui Fan,
Shiping Guo,
Shuangping Zhang Tags: ORIGINAL ARTICLE Source Type: research
Global, regional, and national burden and trends of early ‐onset tracheal, bronchus, and lung cancer from 1990 to 2019
ConclusionsAlthough global efforts have been the most successful and effective in reducing the burden of EO-TBL cancer over the past three decades, there was strong regional and gender heterogeneity. EO-TBL cancer need more medical attention in the lower SDI quintiles and in the female population. (Source: Thoracic Cancer)
Source: Thoracic Cancer - February 2, 2024 Category: Cancer & Oncology Authors: Jun Ma,
Ying ‐da Song,
Xiao‐ming Bai Tags: ORIGINAL ARTICLE Source Type: research
Issue Information
(Source: Thoracic Cancer)
Source: Thoracic Cancer - February 2, 2024 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research
Peripheral arterial rather than venous blood is a better source of circulating tumor cells in early lung cancer
ConclusionCTC levels in peripheral arterial and venous blood differed little in lung cancer patients.Compared to peripheral venous blood, peripheral arterial blood had a higher CTC positivity rate in early-stage lung cancer.This study was favorable for early detection and monitoring of lung cancer. (Source: Thoracic Cancer)
Source: Thoracic Cancer - February 1, 2024 Category: Cancer & Oncology Authors: Zhen ‐dan Wang,
Yi‐fei Feng,
Yu‐shuo Wang,
Ying Ma,
Jiyan Liu,
Dihua Li,
Sheng Li,
Guo‐dong Zhang Tags: ORIGINAL ARTICLE Source Type: research
Prognostic implications of neutrophil ‐to‐lymphocyte ratio in patients with extensive‐stage small cell lung cancer receiving chemoimmunotherapy: A multicenter, real‐world study
ConclusionNLRT2 and irAEs can predict the prognosis of ES-SCLC patients with first-line ES-SCLC receiving PD-L1 inhibitors combined with chemotherapy. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 31, 2024 Category: Cancer & Oncology Authors: Huanhuan Bi,
Dunqiang Ren,
Yuting Xiao,
Yinxue Zhou,
Bingqian Yi,
Weizhong Han,
Yanmei Shao,
Jingluan Wang,
Chunling Zhang,
Hongmei Wang Tags: ORIGINAL ARTICLE Source Type: research
Robotic ‐assisted bronchoscopy for the diagnosis of peripheral pulmonary lesions: A systematic review and meta‐analysis
In conclusion, RAB is an effective and safe technique for PPLs diagnosis. Further high-quality prospective studies still need to be conducted. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 30, 2024 Category: Cancer & Oncology Authors: Chunxi Zhang,
Fangfang Xie,
Runchang Li,
Ningxin Cui,
Felix J. F. Herth,
Jiayuan Sun Tags: REVIEW Source Type: research
Safety of flexible bronchoscopy and clinical course for elderly patients with suspected primary lung cancer
ConclusionsThis study suggests that flexible bronchoscopy can be performed as safely in the elderly as in the nonelderly. Furthermore, even elderly patients may have a greater chance of receiving treatment when a definitive diagnosis is achieved. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 29, 2024 Category: Cancer & Oncology Authors: Zentaro Saito,
Issei Oi,
Takanori Ito,
Takuma Imakita,
Osamu Kanai,
Kohei Fujita,
Tadashi Mio Tags: ORIGINAL ARTICLE Source Type: research
Efficacy and safety of 40 mg osimertinib administered every other day for non‐small cell lung cancer harboring an epidermal growth factor receptor mutation: A single‐center retrospective cohort study
In this study, we examined the efficacy of 40 mg of osimertinib administered every other day. In this single-center, retrospective study, we evaluated patients with NSCLC harboring anEGFR mutation in whom treatment was initiated with 40 mg osimertinib every other day at our institution between May 2016 and June 2023. The major outcome was the duration of administering 40 mg osimertinib every other day. Six patients with NSCLC were evaluated. The median duration of 40 mg osimertinib intake every other day was 12.6 months. F our of the six patients weighed below 50 kg, and four experienced weight loss. Additiona...
Source: Thoracic Cancer - January 28, 2024 Category: Cancer & Oncology Authors: Ayumu Otsuki,
Naoki Inoshima,
Kentaro Tochigi,
Hiroyuki Ito,
Kei Nakashima Tags: BRIEF REPORT Source Type: research
Factors associated with prolonged progression ‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer
ConclusionsWe found thatEGFR-mutated NSCLC patients receiving first-line afatinib were prone to shorter PFS if they had distant organ metastasis, especially liver metastasis. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 27, 2024 Category: Cancer & Oncology Authors: Li ‐Chung Chiu,
Ping‐Chih Hsu,
Chin‐Chou Wang,
How‐Wen Ko,
Scott Chih‐Hsi Kuo,
Jia‐Shiuan Ju,
Pi‐Hung Tung,
Allen Chung‐Cheng Huang,
Cheng‐Ta Yang Tags: ORIGINAL ARTICLE Source Type: research
